HCLTECH
HCLTech, a leading global technology company, will join forces with key stakeholders from across the globe at the 54th Annual Meeting of the World Economic Forum (WEF) in Davos from Jan. 15–19, 2024. The company will contribute to deliberations on this year’s theme of “Rebuilding Trust” and discovering solutions with transparency, consistency and accountability.
HCLTech will be represented by its Chairperson Roshni Nadar Malhotra, CEO and Managing Director C Vijayakumar, Chief Technology Officer Kalyan Kumar; Chief Growth Officer for Europe and Africa, Ashish Kumar Gupta; President, Digital Foundation Services, Jagadeshwar Gattu; Global Head, Financial Services, Srinivasan Seshadri; Chief Marketing Officer Jill Kouri and Global Head, Sustainability, Santhosh Jayaram.
HCLTech will once again host guests at its pavilion at the iconic Promenade 66 which will be fully powered by locally produced green energy, underscoring the company’s commitment to a sustainable planet. In addition to its differentiated portfolio of services across digital, engineering, cloud, AI and software, HCLTech will showcase its award-winning sustainability solution, Net Intelligent Zero (NIO), at the pavilion with a live data feed.
This year, HCLSoftware makes its WEF debut with a dedicated lounge within the HCLTech pavilion. Chief Revenue Officer Rajiv Shesh and Chief Product Officer Kalyan Kumar will lead the HCLSoftware contingent that will showcase its cutting-edge software solutions that help enterprises navigate digital transformation.
HCLTech will participate in and host a series of panels and sessions on the future of technology, sustainability, diversity and inclusion in line with its brand purpose of bringing together the best of technology and its people to supercharge progress.
- The highlight this year will be the ‘Heroes of Progress’ reception on Jan. 17 to honor WEF Global Shapers who are making significant contributions to the fields of environment, women’s empowerment, art and sustainability.
- Roshni Nadar Malhotra, Chairperson, HCLTech is discussing the global water cycle and the potential of water as an enabler for SDGs on a panel on 'Out of Balance with Water' on Jan. 17, 15:00-15:45, Congress Center.
- Srinivasan Seshadri, Chief Growth Officer and Global Head, Financial Services, HCLTech, will lead an affiliate session on ‘Banking on trust through transformative tech’ on Jan. 16, 10:15-11:15 at Dome C, Ice Village.
- HCLTech is conducting broadcast sessions at its pavilion on Jan. 16, 17 and 18, 13:00–13:45. Dr. Saikat Chaudhuri, Innovation, Strategy and Engineering Professor, UC Berkeley will be moderating all three sessions with key industry leaders on: technology-led disruption, opportunities and impact; diversity-led progress for the future workforce; purpose-led sustainability agenda.
Additionally, HCL Group and Uplink, the open innovation platform of WEF, will announce the winners of this year’s Aquapreneur Challenge as part of their ongoing partnership.
To learn more about HCLTech@WEF 2024 visit World Economic Forum (WEF) 2024 at Davos | HCLTech.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111423911/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom